The Lancet Diabetes & Endocrinology最新文献

{"title":"Should diabetes diagnostic thresholds be lowered? Insights from the Middle East","authors":"Barrak Alahmad, Faisal H Al-Refaei, Fahd Al-Mulla, Hamad Ali","doi":"10.1016/s2213-8587(25)00125-1","DOIUrl":"https://doi.org/10.1016/s2213-8587(25)00125-1","url":null,"abstract":"No Abstract","PeriodicalId":48790,"journal":{"name":"The Lancet Diabetes & Endocrinology","volume":"56 1","pages":""},"PeriodicalIF":44.5,"publicationDate":"2025-05-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143901142","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction to Lancet Diabetes Endocrinol 2025; published online April 28. https://doi.org/10.1016/S2213-8587(25)00022-1","authors":"","doi":"10.1016/s2213-8587(25)00132-9","DOIUrl":"https://doi.org/10.1016/s2213-8587(25)00132-9","url":null,"abstract":"<em>Knowler WC, Doherty L, Edelstein SL, et al. Long-term effects and effect heterogeneity of lifestyle and metformin interventions on type 2 diabetes incidence over 21 years in the US Diabetes Prevention Program randomised clinical trial.</em> Lancet Diabetes Endocrinol <em>2025; published online April 28. https://doi.org/10.1016/S2213-8587(25)00022-1</em>—In figure 1 in this Article, in the intensive lifestyle intervention arm, the number of individuals enrolled in the DPPOS should have been 916. Additionally, in the Introduction section, the final sentence of the first paragraph should have read, “…in participants treated with metformin, with an RD [rate difference] of –3·2 cases per 100 person-years”, and in the Results section, the second sentence of the third paragraph should have read, “The estimated cumulative incidence up to 21 years was 69·9%...”. Appendix 2 has also been corrected. These corrections have been made to the online versions as of May 1, 2025, and the printed version will be correct.","PeriodicalId":48790,"journal":{"name":"The Lancet Diabetes & Endocrinology","volume":"13 1","pages":""},"PeriodicalIF":44.5,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143897826","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Redifferentiation therapy in unresectable or metastatic radioactive iodine refractory thyroid cancer: an International Thyroid Oncology Group statement","authors":"Sophie Leboulleux, Laura Boucai, Naifa Busaidy, Cosimo Durante, James A Fagin, Sasan Fazeli, Andrew G Gianoukakis, Bryan R Haugen, Hyunseok Kang, Bhavana Konda, Theodore W Laetsch, Laura Locati, Mabel Ryder, Christine Spitzweg, Francis P Worden, Lori Wirth, Alan Ho","doi":"10.1016/s2213-8587(25)00064-6","DOIUrl":"https://doi.org/10.1016/s2213-8587(25)00064-6","url":null,"abstract":"In patients with follicular cell-derived thyroid cancer that have distant metastases and no iodine uptake, redifferentiation—ie, the restoration of tumoural ¹³¹I uptake with systemic therapy—is now possible. The use of mitogen-activated protein kinase (MAPK) inhibitors for a short period of time before the administration of high activity ¹³¹I shows promising results with iodine uptake restoration and tumour response. Redifferentiation has been used in patients with <em>BRAF</em>-mutated and <em>RAS</em>-mutated tumours in prospective trials and in the case of patients with <em>RET</em> or <em>NTRK</em> fusions. The iodine uptake restoration ranges from 33% to 95%, and tumour response rates from 11% to 80%. There is substantial variability between trials with regards to inclusion criteria, duration of redifferentiation drug therapy, activity of radioactive iodine, and use of dosimetry. Randomised studies are missing to clearly establish the effectiveness and applicability of redifferentiation. Thus, long-term studies are needed to establish the most effective redifferentiation protocols. The objectives of this Review are to: (1) provide a comprehensive review of the available results from prospective trials and case reports, including results regarding the restoration of radioiodine uptake and treatment efficacy (morphological and biological); (2) describe the differences in redifferentiation trial design between studies and discuss their potential impact on treatment efficacy; (3) describe the implications and limitations of dosimetry; and (4) outline the key questions to be addressed in future redifferentiation trials.","PeriodicalId":48790,"journal":{"name":"The Lancet Diabetes & Endocrinology","volume":"47 1","pages":""},"PeriodicalIF":44.5,"publicationDate":"2025-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143893894","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction to Lancet Diabetes Endocrinol 2025; published online April 25. https://doi.org/10.1016/S2213-8587(25)00053-1","authors":"","doi":"10.1016/s2213-8587(25)00130-5","DOIUrl":"https://doi.org/10.1016/s2213-8587(25)00130-5","url":null,"abstract":"<em>Atila C, Chifu I, Drummond JB, et al. A novel diagnostic score for diagnosing arginine vasopressin deficiency (central diabetes insipidus) or primary polydipsia with basal laboratory and clinical parameters: results from two international multicentre prospective diagnostic studies.</em> Lancet Diabetes Endocrinol <em>2025; published online April 25. https://doi.org/10.1016/S2213-8587(25)00053-1</em>—In this Article, the title should have been “A novel diagnostic score for diagnosing arginine vasopressin deficiency (central diabetes insipidus) or primary polydipsia with basal laboratory and clinical parameters: results from two international multicentre prospective diagnostic studies”. This correction has been made to the online version as of April 30, 2025, and the printed version will be correct.","PeriodicalId":48790,"journal":{"name":"The Lancet Diabetes & Endocrinology","volume":"87 1","pages":""},"PeriodicalIF":44.5,"publicationDate":"2025-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143893912","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Does tirzepatide treatment improve skeletal muscle composition?","authors":"Norbert Stefan","doi":"10.1016/s2213-8587(25)00054-3","DOIUrl":"https://doi.org/10.1016/s2213-8587(25)00054-3","url":null,"abstract":"No Abstract","PeriodicalId":48790,"journal":{"name":"The Lancet Diabetes & Endocrinology","volume":"94 1","pages":""},"PeriodicalIF":44.5,"publicationDate":"2025-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143893892","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction to Lancet Diabetes Endocrinol 2025; published online April 25. https://doi.org/10.1016/S2213-8587(25)00067-1","authors":"","doi":"10.1016/s2213-8587(25)00129-9","DOIUrl":"https://doi.org/10.1016/s2213-8587(25)00129-9","url":null,"abstract":"<em>Choy KW, Chiang C. Diagnosing arginine vasopressin deficiency and primary polydipsia.</em> Lancet Diabetes Endocrinol <em>2025; published online April 25. https://doi.org/10.1016/S2213-8587(25)00067-1</em>—In this Comment, the Article name for reference 5 should have been “A novel diagnostic score for diagnosing arginine vasopressin deficiency (central diabetes insipidus) or primary polydipsia with basal laboratory and clinical parameters: results from two international multicentre prospective diagnostic studies”. This correction has been made to the online version as of April 30, 2025, and the printed version will be correct.","PeriodicalId":48790,"journal":{"name":"The Lancet Diabetes & Endocrinology","volume":"8 1","pages":""},"PeriodicalIF":44.5,"publicationDate":"2025-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143893895","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tirzepatide and muscle composition changes in people with type 2 diabetes (SURPASS-3 MRI): a post-hoc analysis of a randomised, open-label, parallel-group, phase 3 trial","authors":"Naveed Sattar, Ian J Neeland, Olof Dahlqvist Leinhard, Laura Fernández Landó, Ross Bray, Jennifer Linge, Angel Rodriguez","doi":"10.1016/s2213-8587(25)00027-0","DOIUrl":"https://doi.org/10.1016/s2213-8587(25)00027-0","url":null,"abstract":"&lt;h3&gt;Background&lt;/h3&gt;Substantial weight reduction is often associated with loss of muscle mass. Tirzepatide has been associated with significant reductions in body weight in type 2 diabetes trials and a beneficial effect on body fat distribution in the SURPASS-3 MRI substudy. This post-hoc exploratory analysis studied the association of tirzepatide treatment with changes in thigh muscle volume, muscle volume Z score, and muscle fat infiltration, and aimed to contextualise the results using longitudinal MRI data from UK Biobank participants.&lt;h3&gt;Methods&lt;/h3&gt;SURPASS-3 was a randomised, open-label, parallel-group, phase 3 trial. The multicentre (45 sites) and multinational (eight countries) MRI substudy of SURPASS-3 enrolled insulin-naive adults (aged ≥18 years) with type 2 diabetes who were on treatment with metformin with or without a sodium–glucose co-transporter-2 (SGLT-2) inhibitor, had an HbA&lt;sub&gt;1c&lt;/sub&gt; of 7·0–10·5% (53–91 mmol/mol), a BMI of at least 25 kg/m&lt;sup&gt;2&lt;/sup&gt;, and a fatty liver index of at least 60. Participants were randomly assigned (1:1:1:1) to receive subcutaneous injection once per week of tirzepatide (5, 10, or 15 mg), or subcutaneous injection once per day of titrated insulin degludec. Thigh muscle fat infiltration, muscle volume, and muscle volume Z score (invariant to sex, height, weight, and BMI) were quantified by MRI at baseline and week 52. In this post-hoc analysis, we assessed the differences between mean baseline and week 52 muscle composition values in the tirzepatide groups (pooled 5 mg, 10 mg, and 15 mg group, and per dose group) and insulin degludec group using paired &lt;em&gt;t&lt;/em&gt; tests, and the differences in muscle composition changes with pooled tirzepatide versus insulin degludec via adjusted ANCOVA models. Observed changes in muscle fat infiltration, muscle volume, and muscle volume Z scores were compared using paired &lt;em&gt;t&lt;/em&gt; tests to population-based estimates calculated from multiple linear regression models fitted to UK Biobank data (n=2942), capturing associations with change in body weight. Analyses were done by modified intention to treat, in the participants enrolled in the MRI substudy with a valid MRI scan at week 52. The SURPASS-3 clinical trial is registered with &lt;span&gt;&lt;span&gt;ClinicalTrials.gov&lt;/span&gt;&lt;svg aria-label=\"Opens in new window\" focusable=\"false\" height=\"20\" viewbox=\"0 0 8 8\"&gt;&lt;path d=\"M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z\"&gt;&lt;/path&gt;&lt;/svg&gt;&lt;/span&gt;, &lt;span&gt;&lt;span&gt;NCT03882970&lt;/span&gt;&lt;svg aria-label=\"Opens in new window\" focusable=\"false\" height=\"20\" viewbox=\"0 0 8 8\"&gt;&lt;path d=\"M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z\"&gt;&lt;/path&gt;&lt;/svg&gt;&lt;/span&gt;, and is complete.&lt;h3&gt;Findings&lt;/h3&gt;Participants were assessed for eligibility and recruited from April 1, 2019, to Nov 15, 2019. Among 502 participants assessed for eligibility to participate in the MRI substudy, 296 were enrolled, and 246 had a valid week 52 MRI scan","PeriodicalId":48790,"journal":{"name":"The Lancet Diabetes & Endocrinology","volume":"47 1","pages":""},"PeriodicalIF":44.5,"publicationDate":"2025-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143893913","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction to Lancet Diabetes Endocrinol 2025; 13: 374–83","authors":"","doi":"10.1016/s2213-8587(25)00128-7","DOIUrl":"https://doi.org/10.1016/s2213-8587(25)00128-7","url":null,"abstract":"<em>Orandi BJ, Chen Y, Li Y, et al.. GLP-1 receptor agonists in kidney transplant recipients with pre-existing diabetes: a retrospective cohort study.</em> Lancet Diabetes Endocrinol 2025; 13: <em>374–83</em>—In figure 1 and table 2 of this Article, precise data in cells with 11 or fewer patients should have been suppressed. These corrections have been made to the online version as of April 29, 2025.","PeriodicalId":48790,"journal":{"name":"The Lancet Diabetes & Endocrinology","volume":"12 1","pages":""},"PeriodicalIF":44.5,"publicationDate":"2025-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143893893","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diabetes prevention: current promise and future directions","authors":"Mary Beth Weber","doi":"10.1016/s2213-8587(25)00055-5","DOIUrl":"https://doi.org/10.1016/s2213-8587(25)00055-5","url":null,"abstract":"No Abstract","PeriodicalId":48790,"journal":{"name":"The Lancet Diabetes & Endocrinology","volume":"8 1","pages":""},"PeriodicalIF":44.5,"publicationDate":"2025-04-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143884699","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-term effects and effect heterogeneity of lifestyle and metformin interventions on type 2 diabetes incidence over 21 years in the US Diabetes Prevention Program randomised clinical trial","authors":"William C Knowler, Lindsay Doherty, Sharon L Edelstein, Peter H Bennett, Dana Dabelea, Mary Hoskin, Steven E Kahn, Rita R Kalyani, Catherine Kim, F Xavier Pi-Sunyer, Sridharan Raghavan, Vallabh O Shah, Marinella Temprosa, Elizabeth M Venditti, David M Nathan","doi":"10.1016/s2213-8587(25)00022-1","DOIUrl":"https://doi.org/10.1016/s2213-8587(25)00022-1","url":null,"abstract":"&lt;h3&gt;Background&lt;/h3&gt;In the US Diabetes Prevention Program (DPP), a 3-year randomised clinical trial in 3234 adults with prediabetes, type 2 diabetes incidence was reduced by 58% with intensive lifestyle intervention (ILS) and by 31% with metformin, compared with placebo. We sought to assess the long-term effects and potential heterogeneity of treatment effects over approximately 21 years of follow-up.&lt;h3&gt;Methods&lt;/h3&gt;The DPP trial was continued with protocol modifications as the DPP Outcomes Study (DPPOS). In the DPPOS, placebo was discontinued, metformin (850 mg twice a day as tolerated) was continued after unmasking, and group-based booster intervention classes were offered to the ILS group twice a year; additionally, all participants were offered group-based lifestyle intervention four times a year. The prespecified primary outcome during DPP and DPPOS was diabetes incidence defined by American Diabetes Association criteria. The DPPOS protocol specified continued diabetes incidence as an outcome; Feb 23, 2020, was chosen as the closing date for the present analysis, as a date prior to the COVID-19 pandemic, which caused major disruptions in clinic visits and complicated longitudinal data analyses. We assessed long-term persistence of intervention effects on diabetes incidence, and heterogeneity of effects in subgroups defined by baseline diabetes risk factors. Follow-up is reported for the combined study from July 31, 1996, to Feb 23, 2020, and analysis was by intention to treat. The trial is registered with &lt;span&gt;&lt;span&gt;ClinicalTrials.gov&lt;/span&gt;&lt;svg aria-label=\"Opens in new window\" focusable=\"false\" height=\"20\" viewbox=\"0 0 8 8\"&gt;&lt;path d=\"M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z\"&gt;&lt;/path&gt;&lt;/svg&gt;&lt;/span&gt;, &lt;span&gt;&lt;span&gt;NCT00004992&lt;/span&gt;&lt;svg aria-label=\"Opens in new window\" focusable=\"false\" height=\"20\" viewbox=\"0 0 8 8\"&gt;&lt;path d=\"M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z\"&gt;&lt;/path&gt;&lt;/svg&gt;&lt;/span&gt; (DPP) and &lt;span&gt;&lt;span&gt;NCT00038727&lt;/span&gt;&lt;svg aria-label=\"Opens in new window\" focusable=\"false\" height=\"20\" viewbox=\"0 0 8 8\"&gt;&lt;path d=\"M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z\"&gt;&lt;/path&gt;&lt;/svg&gt;&lt;/span&gt; (DPPOS); follow-up is ongoing but the trial is closed to enrolment except for previous DPP participants.&lt;h3&gt;Findings&lt;/h3&gt;3195 participants originally enrolled in the DPP were included in the present analyses. This population comprised 2171 (67·9%) female participants and 1024 (32·1%) male participants, with a mean baseline age of 50·6 years (SD 10·7). Individual follow-up times ranged from 0·2 to 23·2 years (median 8·0 years [IQR 3·0 to 18·0]); remaining numbers at risk decreased sharply after 21 years because of administrative censoring and thus follow-up was considered to represent a 21-year period. During follow-up, compared with placebo, diabetes incidence rate was reduced in the original ILS group (hazard ratio [HR] 0·76 [95","PeriodicalId":48790,"journal":{"name":"The Lancet Diabetes & Endocrinology","volume":"69 1","pages":""},"PeriodicalIF":44.5,"publicationDate":"2025-04-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143884800","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}